Reistone Biopharma Company Limited
Clinical trials sponsored by Reistone Biopharma Company Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Drug interaction study aims to unlock safer dosing for new lung therapy Results expected Sep 2026 (estimated)
- New ointment RSS0393 aims to clear psoriasis in major trial Results expected Jan 2027 (estimated)
-
New ointment RSS0393 aims to clear psoriasis in major trial
Disease control Not yet recruitingThis phase 3 trial tests whether RSS0393 ointment can improve plaque psoriasis compared to a placebo. About 600 adults with mild-to-moderate psoriasis will apply the ointment daily for 8 weeks. The main goal is to see if more people achieve clear or almost-clear skin with RSS0393…
Phase 3 • Sponsor: Reistone Biopharma Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Drug interaction study aims to unlock safer dosing for new lung therapy
Knowledge-focused Not yet recruitingThis study examines how the antibiotics rifampicin and clarithromycin change the way the body processes an experimental drug called RSS0343. RSS0343 is being developed for chronic lung and sinus diseases like bronchiectasis and COPD. The trial enrolls 40 healthy adults aged 18 to…
Phase 1 • Sponsor: Reistone Biopharma Company Limited • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC